Dry Eye: Clinical Trials

37 trials for Dry Eye, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

37 completed. 37 Phase 3, 6 Phase 2.

By phase and status

PhaseTrialsStatus
Phase 337Completed 37
Phase 26Completed 6

Follow Dry Eye: new trials by email Literature Review of Dry Eye trials Research Report on Dry Eye

Trials (filtered) newest first · largest first

All 37 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Efficacy and Safety of SJP-0132 Eye Drops in Chinese Patients With Dry Eye Disease
SJP-0132, Placebo - Dry Eye
Phase 3CompletedSenju Pharmaceutical Science & Technology (Beijing) Co., Ltd.4272024-12-302025-11-26
Comparing Efficacy of Autologous Serum Eye Drops With and Without Insulin in Autoimmune Dry Eye.
recombinant human insulin, Autologous serum - Dry Eye, Sjogren Syndrome
Phase 3CompletedInstituto de Oftalmología Fundación Conde de Valenciana252024-02-012026-08-27
Efficacy and Safety of Different Hyaluronic Acid Tear Substitutes Formulations in Evaporative Dry Eye
Icross tear substitute, Hyabak tear substitute - Dry Eye
Phase 2 / Phase 3CompletedUniversity of Seville302023-11-012024-07-26
Comparing Efficacy and Safety of TJO-083 in Dry Eye Diseases Patients
TJO-083, Diquafosol ophthalmic sodium solution 3% - Dry Eye, Dry Eye Syndromes
Phase 3CompletedTaejoon Pharmaceutical Co., Ltd.2712023-07-142025-04-22
Efficacy and Safety of a Multiple-Action Tear Substitute (TriMix) in Dry Eye Disease
Trimix tear substitutes, Hyaluronic acid tear substitute - Dry Eye
Phase 2 / Phase 3CompletedUniversity of Seville1242023-07-012024-06-27
Cyclosporine 0.1% / Loteprednol 0.2% Effect on Anterior Segment Normalization
Klarity CL, Cylcosporine 0.1%/Loteprednol Etabonate 0.2% Preservative Free - Dry Eye
Phase 3CompletedResearch Insight LLC592022-06-032023-01-04
Safety and Efficacy Study on Cenegermin (Oxervate®) vs Vehicle in Severe Sjogren's Dry Eye Disease (PROTEGO-1 Study)
Oxervate, Vehicle - Dry Eye
Phase 3CompletedDompé Farmaceutici S.p.A1042022-01-192024-06-07
A Phase 3, Multi-Center Study Evaluating PL9643 in Patients with Dry Eye
Vehicle Ophthalmic Solution, PL9643 Ophthalmic Solution - Dry Eye, Dry Eye Syndromes
Phase 3CompletedPalatin Technologies, Inc5752021-12-302024-10-17
A Study to Assess the Efficacy and Safety of Tanfanercept (HL036) Ophthalmic Solution in Participants With Dry Eye
0.25% Tanfanercept Ophthalmic Solution, Placebo - Dry Eye
Phase 3CompletedHanAll BioPharma Co., Ltd.2602021-11-182023-10-23
The Effect of a Novel Blueberry Supplement on Dry Eye Disease
Blueberry gummy, Placebo gummy - Dry Eye
Phase 3CompletedSightSage Foods and Nutrition Inc.682021-09-092023-01-20
The TRANQUILITY 2 Trial: A Phase 3 Clinical Trial to Assess the Efficacy and Safety in Subjects With Dry Eye Disease
Reproxalap Ophthalmic Solution (0.25%), Vehicle Ophthalmic Solution - Dry Eye
Phase 3CompletedAldeyra Therapeutics, Inc.3612021-08-282025-03-18
ALY688 Ophthalmic Solution in Subjects With Dry Eye Disease
ALY688 Ophthalmic Solution - Dry Eye
Phase 2 / Phase 3CompletedAllysta Pharmaceutical9222021-05-192023-03-16
A Study Evaluating HBM9036 Efficacy and Safety on Moderate to Severe Dry Eye
HBM9036 0.25% Ophthalmic Solution, Placebo - Dry Eye
Phase 3CompletedHarbour BioMed (Guangzhou) Co. Ltd.5772021-02-252026-04-28
The TRANQUILITY Trial: Clinical Trial to Assess the Efficacy and Safety in Subjects With Dry Eye Disease
Reproxalap Ophthalmic Solution (0.25%), Vehicle Opthalmic Solution - Dry Eye, Dry Eye Syndromes
Phase 2 / Phase 3CompletedAldeyra Therapeutics, Inc.3292020-11-212025-03-19
Assess the Safety and Efficacy of CsA Ophthalmic Gel in Subjects With Moderate to Severe Dry Eye Disease
CsA Ophthalmic Gel, Placebo, Hypromellose Eye Drop - Dry Eye
Phase 3CompletedZhaoke (Guangzhou) Ophthalmology Pharmaceutical Ltd.6442020-11-052022-04-29
Phase 3 Study of the Safety and Efficacy of OmegaD Softgels in the Treatment of Dry Eye Disease
Omega 3 fatty acid, Placebos - Dry Eye
Phase 3CompletedOmegaD LLC3222019-11-182024-07-29
Assessment of the Safety and Efficacy of RGN-259 Ophthalmic Solutions for Dry Eye Syndrome: ARISE-3
RGN-259, Placebo - Dry Eye Syndromes, Dry Eye
Phase 3CompletedReGenTree, LLC7002019-05-242026-08-28
The RENEW Trial: A Multi-Center, Randomized, Double-Masked, Parallel-Group, Vehicle-Controlled, Adaptive Phase 3 Clinical Trial to Assess the Safety and Efficacy of Subjects With Dry Eye Disease
Reproxalap Ophthalmic Solution (0.25%) QID, Vehicle Ophthalmic Solution QID, Reproxalap Ophthalmic Solution (0.25%) QID to BID - Dry Eye
Phase 3CompletedAldeyra Therapeutics, Inc.4222019-04-162025-01-23
Tavilermide Ophthalmic Solution for the Treatment of Dry Eye
Tavilermide ophthalmic solution, Placebo - Keratoconjunctivitis Sicca, Dry Eye
Phase 3CompletedMimetogen Pharmaceuticals USA, Inc.6232019-03-282023-04-05
A Study to Assess Efficacy and Safety of HL036 in Subjects With Dry Eyes
HL036 Ophthalmic Solution, Placebo - Dry Eye
Phase 3CompletedHanAll BioPharma Co., Ltd.6372019-03-102022-04-14

Showing 20 of 37. Sign in to see all of them.

Narrower conditions

Dry Eye Syndromes (37)  ·  Sjogren's Syndrome (4)  ·  Keratoconjunctivitis Sicca (3)  ·  Autoimmune Diseases (1)  ·  Conjunctival Diseases (1)  ·  Corneal Diseases (1)  ·  Eye Diseases (1)  ·  Insulin Resistance (1)

Broader conditions

Lacrimal Apparatus Diseases (37)  ·  Eye Diseases (36)  ·  Arthritis (4)  ·  Arthritis, Rheumatoid (4)  ·  Connective Tissue Diseases (4)  ·  Immune System Diseases (4)  ·  Joint Diseases (4)  ·  Mouth Diseases (4)  ·  Musculoskeletal Diseases (4)  ·  Rheumatic Diseases (4)  ·  Salivary Gland Diseases (4)  ·  Skin and Connective Tissue Diseases (4)  ·  Stomatognathic Diseases (4)  ·  Xerostomia (4)  ·  Autoimmune Diseases (3)

Interventions

Ophthalmic Solutions (2)  ·  Acupuncture Therapy (1)  ·  Brimonidine Tartrate (1)  ·  Carboxymethylcellulose Sodium (1)  ·  Chondroitin (1)  ·  Cyclosporine (1)  ·  Cyclosporins (1)  ·  Fatty Acids, Omega-3 (1)  ·  Fluorometholone (1)  ·  Glycerol (1)  ·  Hydroxychloroquine (1)  ·  Loteprednol Etabonate (1)  ·  Lubricant Eye Drops (1)  ·  Pilocarpine (1)  ·  Pregabalin (1)

Sponsors

Aldeyra Therapeutics, Inc. (3)  ·  HanAll BioPharma Co., Ltd. (2)  ·  OmegaD LLC (2)  ·  University of Seville (2)  ·  Alcon Research (1)  ·  Alexandria University (1)  ·  Allergan (1)  ·  Allysta Pharmaceutical (1)  ·  Dompé Farmaceutici S.p.A (1)  ·  Eyegate Pharmaceuticals, Inc. (1)  ·  Federal University of São Paulo (1)  ·  Harbour BioMed (Guangzhou) Co. Ltd. (1)  ·  Instituto Universitario de Oftalmobiología Aplicada (Institute of Applied Ophthalmobiology) - IOBA (1)  ·  Instituto de Oftalmología Fundación Conde de Valenciana (1)  ·  Korea Institute of Oriental Medicine (1)

Countries

United States (19)  ·  China (3)  ·  South Korea (3)  ·  Spain (3)  ·  Japan (2)  ·  Mexico (2)  ·  Brazil (1)  ·  Canada (1)  ·  Egypt (1)  ·  Italy (1)

Top investigators

Anat Galor, MD, MSPH (1)  ·  Brian Dodge (1)  ·  Ehab Mossallam, PhD (1)  ·  Eiji Murakami (1)  ·  Flavio Mantelli, MD (1)  ·  Gaafar Ragab (1)  ·  Gail L Torkildsen, MD (1)  ·  John Hovanesian, MD (1)  ·  Karen Meerovitch, PhD (1)  ·  Kazunori Omatsu (1)  ·  Margarita Calonge-Cano, MD, PhD (1)  ·  Mark Curtis, O.D. (1)  ·  Maureen G Maguire, PhD (1)

Results publications

PMID 11879137, PMID 14508260, PMID 15604871, PMID 16371776, PMID 17043506, PMID 18848318, PMID 20735287, PMID 21078194, PMID 22615787, PMID 22914501, PMID 26065354, PMID 26365210, PMID 27366013, PMID 27645318, PMID 28079022, PMID 28777385, PMID 29432648, PMID 29545413, PMID 29652551, PMID 29883769, PMID 29970389, PMID 30161055, PMID 31022469, PMID 31116166, PMID 31373862, PMID 31425752, PMID 31445751, PMID 31489258, PMID 32097181, PMID 32821497, PMID 33096271, PMID 33290317, PMID 33530719, PMID 33561944, PMID 34294637, PMID 36575626, PMID 36729473, PMID 37209594, PMID 38345056, PMID 38391283, PMID 39079754, PMID 42803882

NIH funding

U10EY022879 (1), U10EY022881 (1)